Previous 10 | Next 10 |
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2023 financial results on Augu...
2023-06-22 12:17:13 ET Kymera Therapeutics ( NASDAQ: KYMR ) said that its drug candidate KT-253 has received orphan drug status from the the US Food and Drug Administration for the treatment of acute myeloid leukemia. The company initiated Phase 1 testing of the drug in Marc...
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (F...
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models N o dose limiting toxicities observed in either program KT-333 data w...
2023-06-12 14:58:00 ET Shares of Kymera Therapeutics ( NASDAQ: KYMR ) rose as much as 15% on Monday amid the release of preclinical and early-stage clinical data for three of its drug candidates for blood cancer. Kymera shares were up 8% at $24.61 at around 2:50 p.m. after hitti...
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose limiting toxicities observed Data on additional KT-333 and KT-413 patient...
WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, will present preclinical data on KT-253, a potent and s...
2023-06-02 10:02:23 ET Gainers: Connect Biopharma ( CNTB ) +26% . LAVA Therapeutics ( LVTX ) +19% . Panbela Therapeutics ( PBLA ) +18% . Apollomics ( APLM ) +15% . Rockwell Medical ( RMTI ) +10% . Losers: Kiora Pharm...
2023-06-01 17:29:40 ET Gainers: LAVA Therapeutics ( LVTX ) +24% . MongoDB ( MDB ) +23% . lululemon athletica ( LULU ) +13% . Stratasys ( SSYS ) +7% . Everbridge ( EVBG ) +6% . Losers: Braze ( BRZE ) -5% ...
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team wil...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...